Endothelin-1 and vein graft occlusion in patients undergoing bypass surgery

Area of Science:

• Vascular Surgery
• Cardiovascular Research
• Pharmacology

Background:

• Saphenous vein grafts are crucial for revascularization in coronary artery disease and critical limb ischemia but suffer from poor patency rates.
• Graft failure stems from early occlusion (vasoconstriction, thrombus) and later issues (neointimal hyperplasia, atherosclerosis).
• Endothelin-1, a peptide implicated in vascular diseases, is released during surgical trauma and affects vein graft reactivity and structure.

Purpose of the Study:

• To review the role of endothelin-1 in saphenous vein graft occlusion.
• To discuss the therapeutic potential of endothelin receptor antagonists in enhancing vein graft performance.

Main Methods:

• Review of existing data on endothelin-1's effects on saphenous vein segments (human and animal).
• Examination of in vitro studies on endothelin-1-induced vascular smooth muscle proliferation and neointimal thickening.
• Analysis of experimental data using endothelin receptor antagonists (subtype-selective and dual).

Main Results:

• Endothelin-1 causes significant vasoconstriction in isolated saphenous vein segments.
• Endothelin-1 promotes vascular smooth muscle cell proliferation and neointimal thickening in vitro via endothelin A and B receptors.
• Experimental antagonists have demonstrated the ability to inhibit these endothelin-1-mediated effects.

Conclusions:

• Endothelin-1 plays a significant role in the pathophysiology of saphenous vein graft occlusion.
• Endothelin receptor antagonists represent a promising therapeutic strategy to improve vein graft patency and long-term outcomes.